

Yearly Eye Exam for Patients on Hydroxychloroquine Sulfate (Plaquenil)

The Problem

Hydroxychloroquine Sulfate (Plaquenil) is associated with retinal toxicity. Therefore, it is recommended that patients who are using Plaquenil get an eye exam done yearly.

Aim/Goal

To ensure that all patients seen in the Division of Rheumatology and are on Hydroxychloroquine Sulfate (Plaquenil) receive eye examinations at least yearly.

The Team


Robert Shmerling, MD, Naama Neeman, MSc, Joanne Schulze, Mark D. Aronson, MD

The Interventions

- The Rheumatology division has reached a consensus regarding the importance of tracking the percentage of their patients who are using Plaquenil and receive an annual eye exam.
- Data was collected using administrative billing lists as well as the review of electronic medical records.
- Data was recorded and trended in the Rheumatology QI Dashboard.
- Feedback in the Division's performance was provided via emails and faculty meetings.
- Quarterly confidential individual scorecards gave each clinician feedback regarding their performance as compared to that of the entire Division's faculty.

The Results

The percentage of patients on Plaquenil seen in the Rheumatology Ambulatory Service who had a documented eye exam performed in the past 12 months (from the last visit date) increased from 65% in Q1 2006 to 100% in Q3 2008.




Next Steps

Continue to monitor this QI measure with the goal of maintaining 100% compliance in 2009.



Beth Israel Deaconess
Medical Center



THE SILVERMAN INSTITUTE
For Healthcare Quality and Safety

For More Information Contact
Naama Neeman, MSc, Medicine QI Project Manager
(nneeman@bidmc.harvard.edu)